The global injectable drug delivery devices market size is anticipated to reach USD 823.29 billion by 2030, according to a new report by Grand View Research, Inc. The market is projected to grow at a CAGR of 8.7% from 2024 to 2030. The increase in the number of chronic diseases like diabetes and cancer has fueled the need for injectable drug delivery. Unlike other traditional forms of drug delivery, injectables allow maximum bioavailability of the pharmaceutical drug as it bypasses the first-pass metabolism. With substantial growth in technological advancements, the devices being manufactured and marketed are built so as to cater to the specific needs of the patients.
With the advent of self-injection devices, injectable drugs can be self-administered without the need for medical assistance. A large number of technology-oriented developments have taken place in the biologics market, which further increases the applicability of these injectable devices in the challenging disease areas. Self-injection devices have allowed patients suffering from diabetes to manage insulin levels with auto-injectors, pen-injectors, and needle-free injectors; thus, the homecare segment has been a large grosser in the end-user application.
The major restraints in this market are injuries and infections caused by needles, ambiguities related to regulatory reimbursements, sterility of the injectable drugs, and the preference of other drug delivery systems that possess less toxicity and are easy to administer. Despite these restraints, the market potential for injectable drug delivery products is tremendous with the majority of the key players opting to injectables over other forms of delivery. The injectable drug delivery industry, based on product type is segmented into two sub-types namely self-injection devices and conventional injection devices. Further, on the basis of therapeutic use, the injectable drug delivery industry is segmented into autoimmune disorders, hormonal disorders, oncology, and others.
The injectable drug delivery industry by end-user application is categorized into hospitals, home care settings, and others including research establishments, diagnostics, and clinical laboratories.
Request a free sample copy or view report summary: Injectable Drug Delivery Devices Market Report
Oncology is anticipated to witness the fastest CAGR of 9.3% over the forecast period. This is due to the growing incidence of cancer globally and the evolution of targeted therapies.
Hospitals dominated the market with 53.2% share in 2023. Hospitals are increasingly adopting advanced injectable devices due to their ability to provide rapid therapeutic effects, which is crucial in emergency care and critical situations.
North America injectable drug delivery devices market dominated with 40.5% market share in 2023. North America has a significant population with chronic diseases such as diabetes, cancer, and autoimmune disorders.
Grand View Research has segmented the global injectable drug delivery devices market on the basis of product, therapeutic use, end-use, and region:
Injectable Drug Delivery Devices Product Outlook (Revenue, USD Million, 2018 - 2030)
Devices
Self-injection devices
Conventional devices
Formulations
Conventional drug delivery
Novel drug delivery
Others
Injectable Drug Delivery Devices Therapeutic Use Outlook (Revenue, USD Million, 2018 - 2030)
Autoimmune disorders
Hormonal disorders
Oncology
Others
Injectable Drug Delivery Devices End-use Outlook (Revenue, USD Million, 2018 - 2030)
Hospitals
Homecare Settings
Others
Injectable Drug Delivery Devices Regional Outlook (Revenue, USD Million, 2018 - 2030)
North America
U.S.
Mexico
Canada
Europe
Germany
France
Italy
Spain
Denmark
Sweden
Norway
Asia Pacific
Japan
China
India
South Korea
Thailand
Australia
Latin America
Brazil
Argentina
MEA
South Africa
Saudi Arabia
UAE
Kuwait
List of Key Players in the Injectable Drug Delivery Devices Market
Baxter
Schott AG
BD
Eli Lilly and Company
Terumo Corporation
Elcam Medical
Unilife Corporation
Ypsomed AG
Gerresheimer AG
Sanofi
"The quality of research they have done for us has been excellent..."